» Articles » PMID: 35395730

Effects of Reduced Gag Cleavage Efficiency on HIV-1 Gag-Pol Package

Overview
Journal BMC Microbiol
Publisher Biomed Central
Specialty Microbiology
Date 2022 Apr 9
PMID 35395730
Authors
Affiliations
Soon will be listed here.
Abstract

Background: HIV-1 pol, which encodes enzymes required for virus replication, is initially translated as a Gag-Pol fusion protein. Gag-Pol is incorporated into virions via interactions with Gag precursor Pr55. Protease (PR) embedded in Gag-Pol mediates the proteolytic processing of both Pr55gag and Gag-Pol during or soon after virus particle release from cells. Since efficient Gag-Pol viral incorporation depends on interaction with Pr55 via its N-terminal Gag domain, the prevention of premature Gag cleavage may alleviate Gag-Pol packaging deficiencies associated with cleavage enhancement from PR.

Results: We engineered PR cleavage-blocking Gag mutations with the potential to significantly reduce Gag processing efficiency. Such mutations may mitigate the negative effects of enhanced PR activation on virus assembly and Gag-Pol packaging due to an RT dimerization enhancer or leucine zipper dimerization motif. When co-expressed with Pr55, we noted that enhanced PR activation resulted in reduced Gag-Pol cis or trans incorporation into Pr55 particles, regardless of whether or not Gag cleavage sites within Gag-Pol were blocked.

Conclusions: Our data suggest that the amount of HIV-1 Gag-Pol or Pol viral incorporation is largely dependent on virus particle production, and that cleavage blocking in the Gag-Pol N-terminal Gag domain does not exert significant impacts on Pol packaging.

Citing Articles

Exploring HIV-1 Maturation: A New Frontier in Antiviral Development.

McGraw A, Hillmer G, Medehincu S, Hikichi Y, Gagliardi S, Narayan K Viruses. 2024; 16(9).

PMID: 39339899 PMC: 11437483. DOI: 10.3390/v16091423.


The HIV-1 Gag Protein Displays Extensive Functional and Structural Roles in Virus Replication and Infectivity.

Marie V, Gordon M Int J Mol Sci. 2022; 23(14).

PMID: 35886917 PMC: 9323242. DOI: 10.3390/ijms23147569.

References
1.
Srinivasakumar N, Hammarskjold M, Rekosh D . Characterization of deletion mutations in the capsid region of human immunodeficiency virus type 1 that affect particle formation and Gag-Pol precursor incorporation. J Virol. 1995; 69(10):6106-14. PMC: 189507. DOI: 10.1128/JVI.69.10.6106-6114.1995. View

2.
Guo T, Yu F, Huang K, Wang C . p6gag domain confers cis HIV-1 Gag-Pol assembly and release capability. J Gen Virol. 2015; 97(1):209-219. DOI: 10.1099/jgv.0.000321. View

3.
Pettit S, Moody M, Wehbie R, KAPLAN A, Nantermet P, Klein C . The p2 domain of human immunodeficiency virus type 1 Gag regulates sequential proteolytic processing and is required to produce fully infectious virions. J Virol. 1994; 68(12):8017-27. PMC: 237265. DOI: 10.1128/JVI.68.12.8017-8027.1994. View

4.
Huang L, Chen C . Understanding HIV-1 protease autoprocessing for novel therapeutic development. Future Med Chem. 2013; 5(11):1215-29. PMC: 3826259. DOI: 10.4155/fmc.13.89. View

5.
Tachedjian G, Orlova M, Sarafianos S, Arnold E, Goff S . Nonnucleoside reverse transcriptase inhibitors are chemical enhancers of dimerization of the HIV type 1 reverse transcriptase. Proc Natl Acad Sci U S A. 2001; 98(13):7188-93. PMC: 34644. DOI: 10.1073/pnas.121055998. View